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ABSTRACT: Cocrystallization has been promoted as an
attractive early development tool as it can change the
physicochemical properties of a target compound and possibly
enable the purification of single enantiomers from racemic
compounds. In general, the identification of adequate cocrystalliza-
tion candidates (or coformers) is troublesome and hampers the
exploration of the solid-state landscape. For this reason, several
computational tools have been introduced over the last two
decades. In this study, cocrystals of Praziquantel (PZQ), an
anthelmintic drug used to treat schistosomiasis, are predicted with
network-based link prediction and experimentally explored. Single
crystals of 12 experimental cocrystal indications were grown and
subjected to a structural analysis with single-crystal X-ray
diffraction. This case study illustrates the power of the link-prediction approach and its ability to suggest a diverse set of new
coformer candidates for a target compound when starting from only a limited number of known cocrystals.
1. INTRODUCTION
Upon their discovery, active pharmaceutical ingredients (APIs)
have physicochemical properties that are often different from
those desired in the final drug product. As a variety of these
properties depend on the crystal structure of the drug
candidate, several methods have been proposed to address
this issue by adjusting the underlying solid-state characteristics.
These methods include screening for polymorphic forms,1,2
multicomponent crystals,3−5 and (co)amorphous phases.6,7
Among these options, cocrystallization has been identified as a
flexible and reliable way to explore different solid forms of an
API due to the abundance of possible cocrystal formers (called
coformers) and the general thermodynamic stability of
cocrystalline phases.8
For APIs containing one or more stereogenic centers, the
administration of the drug in racemic formulations (i.e.,
containing both enantiomers in a stoichiometric ratio) can
introduce unwanted side effects originating from one of the
API’s enantiomers (the so-called distomer). Because the
current industrial climate has shifted toward the acceptance
of only chirally pure drugs,9,10 a severe threat is posed to drugs
that are only obtainable as racemic compounds (covering 90−
95% of the cases)11 and are inherently hard to separate.12
However, the addition of an achiral coformer can prompt the
formation of a conglomerate of enantiopure cocrystals13−16
(i.e., a physical mixture of crystals containing a single
enantiomer and the coformer). This opens a window of
possibilities for crystallization-based separation techniques,
such as preferential crystallization17 and deracemization
methods,18−22 as was recently demonstrated in two separate
case studies for cocrystals of racemic compound-forming
targets.23,24 Moreover, introducing a chiral coformer can lead
either to the formation of a pair of diastereomeric cocrystals or
the formation of an enantiospecific cocrystal (where only one
of the target’s enantiomers interacts with the chiral coformer).
The latter approach has previously been shown to be a viable
strategy for achieving enantiomerically pure substances.25−27
Therefore, the exploration of new cocrystals of racemic
compounds with both achiral and chiral coformers can yield
new forms relevant for chiral separation.
Praziquantel28 (PZQ; Figure 1) is an anthelmintic drug used
in the preventive treatment of schistosomiasis, a disease caused
by parasitic flatworms, and suffers from a number of the above-
mentioned issues. Due to its poor solubility in aqueous media,
the drug is classified as a BCS class II druga, and efforts to
improve its solubility and dissolution profile by screening for
polymorphs,29−34 hydrates,35 and cocrystals29,36,37 have been
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previously reported. Additionally, while PZQ is currently
administered as a racemate, the (R)-enantiomer possesses the
desired therapeutic activity38−41 and the (S)-enantiomer, the
distomer, is held responsible for the drug’s bitter taste and
other unwanted side effects.42 Earlier studies with the aim of
resolving PZQ’s enantiomers have been reported using a
diastereomeric salt of its amine precursor43 and more recently
by the deracemization of a derivative of the amine precursor.44
Finding a suitable conglomerate-forming multicomponent
crystal of PZQ itself could be a worthwhile addition to the
set of solutions applicable for chiral separation, either using
preferential crystallization or deracemization methods. As PZQ
does not contain readily ionizable functional groups, it is
precluded from salt formation; therefore, cocrystallization is
the method of choice for the further exploration of new
multicomponent solid forms. Cocrystals of PZQ with various
dicarboxylic acids29,36 and other pharmaceutically acceptable
compounds37 have previously been reported, and the
structures of several combinations were resolved with single-
crystal X-ray diffraction (SC-XRD) and deposited in the
Cambridge Structural Database (CSD).45 The discovery of a
new set of PZQ cocrystals could potentially form a
breakthrough in the formulation of the drug product and the
cost-effective purification of the desired enantiomer.
In the present research, we evaluate the formation of
cocrystals of PZQ with 30 coformers that were predicted using
network-based link prediction.46 By representing the informa-
tion on cocrystals in the CSD as a network consisting of
coformers with their cocrystals acting as links,47 new cocrystals
can be predicted in the network using mathematical link-
prediction algorithms. A requirement for such algorithms to
function is the availability of some experimental cocrystalliza-
tion data for the target compound. As for PZQ cocrystal data is
indeed available in the CSD, it is an excellent “real-life”
candidate to apply the link-prediction approach. This article
describes the application of the network-based link-prediction
method to predict 30 new coformer candidates for PZQ and
the structural characterization and classification of 12 new
cocrystalline forms of PZQ that were discovered with this
approach.
Figure 1. Praziquantel.
Figure 2. A network containing, from left to right, the target PZQ (blue), coformers known to form cocrystals with PZQ (pink, a−h), and the
coformers (blue) interconnecting PZQ’s known coformers to the candidate 4-hydroxybenzoic acid (pink). The molecular structures of PZQ’s
neighbors are also shown with the six-character codes that correspond to their cocrystal entries in the CSD.
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2. METHODS
To predict new cocrystals for PZQ with network-based link
prediction, a network of coformers must be constructed. By searching
with ConQuest48 (CSD ver. 5.39, November 2017, two updates) for
CSD entries containing two chemical residues that were organic, not
ionic or polymeric, error-free, and had determined three-dimensional
coordinates (including disorder), a list of 34 555 two-component
(binary) cocrystals, solvates, and crystals containing a gas molecule
were found. The components in these entries were found after the
conversion of the corresponding structure data files (SD) to canonical
SMILES strings with OpenBabel,49 and 9141 cocrystals were found by
comparing these components to lists of common gases and solvents.46
To construct a network of coformers, a set of 7141 unique coformers
N was gathered from the above-mentioned list of cocrystals, and an
index was assigned to each coformer. Next, an adjacency matrix A
∈ | |×| |N N , which is the mathematical basis of the network, was built,
and all binary cocrystals with coformer indices i and j were added by
setting Ai,j and Aj,i to a value of 1.
47
As the CSD contains only the collection of cocrystals that have
been successfully determined up to this point in time, it is likely that
an abundance of cocrystals are yet to be discovered. In other words,
the cocrystal network is probably, to a large extent, incomplete. In
fact, it is mathematically possible to identify the missing links (i.e.,
plausible combinations between coformers) with link-prediction
algorithms based on the structure of the network (via the adjacency
matrix A).46 Such algorithms look for coformer candidates that exhibit
a similar tendency to form cocrystals as those known to interact with
the target. This is visualized in Figure 2 for PZQ (the target, blue
node) and 4-hydroxybenzoic acid (the coformer candidate, pink
node). Here, the known coformers of the target compound (PZQ), L-
malic acid (compound a36) and other dicarboxylic acids (compounds
b−h29) (middle pink nodes), have multiple cocrystallization partners
(middle blue nodes) in common with the coformer candidate 4-
hydroxybenzoic acid.
To quantify with link prediction how likely two coformers are to
form a cocrystal, several score indices were proposed and tested.46
Finally, the bipartite resource allocation score index (see Figure 3a)
was selected, as it performed best on the validation data. The
calculation of this score index is based on properties of the
intermediate network between the two coformers and can loosely
be interpreted as a summation of similarities between nodes of equal
color in Figure 3a. The score values obtained with link prediction can
be compared to those of known cocrystals during a validation
experiment (cross validation, for a detailed explanation see ref 46) and
can be related to a precision = +p
TP
TP FP
, where TP is the number of
true positives and FP is the number of false positives for the validation
set at that score value (see Figure 3b). The procedures for the
construction of the coformer network and network-based link
prediction were all performed using the Python programming
language (ver. 3.7.9).
For the present research, the network-based link-prediction
approach was used to compute the scores for PZQ and the 7140
remaining available coformers in the network. Based on their scores,
which ranged from 0 to 9.31, and corresponding precisions, which
ranged from 0 to 49%, the 30 highest-scoring coformers were selected
as candidates for cocrystal screening with racemic PZQ, taking the
estimated number of new cocrystal forms to be discovered into
account. This resulted in 17 new indications for cocrystal formation,
and crystals suitable for single-crystal X-ray diffraction (SC-XRD)
could be grown for a subset of these indications (experimental details
are available in the ESI). An experimental screening strategy, covering
liquid-assisted grinding, solvent evaporation, and the saturation
temperatures of specific component mixtures, was used, which proved
to be essential for a robust screening and discovery of the newly found
cocrystals and will form the topic of a future publication.
3. RESULTS
3.1. Coformer Candidates for PZQ Proposed with
Network-Based Link Prediction. Using the knowledge
gained from eightb cocrystal structures of Praziquantel found
in the CSD (shown in Figure 2), the link-prediction algorithm
was used to predict 30 new coformer candidates (Figure 4 and
Table 1). Scores are calculated for each coformer (ranked in
decreasing order in Table 1) using the local networks between
Figure 3. (a) Visualization of a local intermediate network formed between two coformers i and j, properties of the local network (n and b), and the
bipartite resource allocation score index si,j. (b) Relation between the score and precision values obtained during the cross validation of the method
(see ref 46).
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these coformer candidates and PZQ, which each correspond to
an expected precision value after model validation.
Besides the five aliphatic dicarboxylic acids (four of which
were in fact already considered by Espinosa-Lara et al.29), the
list of 30 predicted coformers includes rather different
compounds, such as benzoic acid derivatives and aromatic
compounds with hydroxyl, amine, and nitro-groups, all of
which present the possibility to form strong intermolecular
interactions with Praziquantel. Salicylic acid and an enantiomer
of tartaric acid are also present in this list, and indications for
cocrystal formation with these compounds were reported
earlier by Cugovcǎn et al.;37 however, their crystal structures
were not revealed. Remarkably, 1,4-diiodotetrafluorobenzene
was also predicted as a coformer for PZQ. This compound is
very dissimilar to any of the other predicted coformer
candidates or coformers already reported for PZQ in the CSD.
It is noteworthy that the predicted score values of the 30
coformers correspond to relatively low precisions, the highest
being 49% and lowest being 17%. One would therefore expect
around nine new cocrystals to emerge from this list (





i , with pi being the precision associated
with coformer i in Table 1). Yet, as already explained in ref 46,
this precision is underestimated and is in fact the lower limit
for its actual value. A larger number of new cocrystals is
therefore expected to emerge from the subsequent exper-
imental screening. Therefore, a unique advantage of this
approach is that it not only predicts a set of suitable coformers
but also estimates how many cocrystals are expected to emerge
from an experimental study.
From the top 30 coformer candidates, 12 yielded one or
several new phases (see Table 1), resulting in 17 indications
Figure 4. The 30 coformers predicted with link prediction for PZQ.
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Table 1. Overview of the Coformers Predicted and Screened for Racemic Praziquantela
rank coformer score precision screening (PXRD) SC-XRD
1 sebacic acid 9.31 0.49 x
2 suberic acid 9.23 0.49 x
3 benzoic acid 8.00 0.47 x
4 pimelic acid 7.54 0.46 √
5 salicylic acid 6.91 0.44 √ √(+H2O)
6 1,4-diiodotetrafluorobenzene 5.82 0.40 √ √
7 4-hydroxybenzoic acid 5.26 0.38 √ √
8 terephthalic acid 5.22 0.38 x
9 4-aminobenzoic acid 4.79 0.36 x
10 isophthalic acid 3.82 0.31 x
11 azelaic acid 3.75 0.30 x
12 4-aminosalicylic acid 3.45 0.28 √ √(+MeCN)
13 3,5-dinitrobenzoic acid 3.34 0.28 √ √
14 trans-cinnamic acid 3.22 0.27 x
15 hydroquinone 3.09 0.26 √, √ √
16 3-hydroxybenzoic acid 3.02 0.26 x
17 anthranilic acid 2.85 0.25 x
18 phthalic acid 2.68 0.24 x
19 D-(−)-tartaric acid 2.67 0.24 x
20 vanillic acid 2.55 0.23 √, √ √
21 4-nitrobenzoic acid 2.33 0.22 x
22 2,5-dihydroxybenzoic acid 2.21 0.21 √, √ √, √(+MeCN)
23 2-fluorobenzoic acid 2.12 0.20 x
24 3,5-dihydroxybenzoic acid 2.10 0.20 √ √(+MeCN)
25 3-nitrobenzoic acid 2.02 0.19 x
26 4-nitrophenol 1.98 0.19 x
27 1-hydroxy-2-naphtoic acid 1.94 0.19 x
28 2,4-hydroxybenzoic acid 1.86 0.18 √, √, √ √
29 orcinol 1.72 0.17 √ √
30 dodecanedioic acid 1.69 0.17 x
a√, new phase observed with powder X-ray diffraction (PXRD) or single-crystal X-ray diffraction (SC-XRD); x, physical mixture or oil of the
constituents observed with powder X-ray diffraction (PXRD).
Figure 5. Structures of four PZQ cocrystals exhibiting similar enantiopure chains. The (S)-enantiomer of PZQ is shown in each structure, and all
hydrogen atoms except those involved in hydrogen bonding interactions and those explanatory for the absolute configuration are omitted. For
clarity, only the major conformation is shown in case of disorder (ORTEP plots with disorder are in the ESI). (a) Cocrystal with 2,5-
dihydroxybenzoic acid (22). (b) Cocrystal solvate with 2,5-dihydroxybenzoic acid (22) and MeCN. (c) Cocrystal with 4-hydroxybenzoic acid (7).
(d) Cocrystal solvate with 4-aminosalicylic acid (12) and MeCN.
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for cocrystal formation. The experimental proof of these new
forms, presented as powder diffractograms, can be found in
Figures S1−S14, and the experimental conditions used for
their synthesis can be found in Table S2 (see the ESI). This
article focuses on the application of network-based link
prediction, briefly introduces the newly identified phases, and
investigates their crystal structures. A thorough description of
the various screening methods, their thermodynamic nature,
and the corresponding results will be discussed in a future
article.
3.2. Structural Analysis of Newly Discovered Cocrys-
tals for PZQ. Single crystals of 12 new cocrystals of racemic
PZQ were successfully grown and analyzed (Table 1). PZQ
molecules are always found in their anti-conformation where
the carbonyl groups face opposite directions, in some cases
with a 90° rotation of the cyclohexyl ring. The crystal
structures can be classified into four classes, based on the
established intermolecular interaction patterns and the packing
of the PZQ enantiomers.
The most frequently occurring class is populated by
cocrystals characterized by one-dimensional enantiopure
chains (Figures 5 and 6) where both carbonyl groups of
PZQ molecules always interact with the coformer through
hydrogen bonds. The crystal structures are centrosymmetric
and therefore also contain chains of the opposite chirality. The
different chains are held together by interactions weaker than
the hydrogen bonds within the chains. Figure 5 shows four
cocrystals characterized by the formation of these similar
chains, where the coformers can be regarded as interchange-
able agents for cocrystal formation. The cocrystal solvates
containing 2,5-dihydroxybenzoic acid (Figure 5b) and 4-
aminosalicylic acid (Figure 5d) are isostructural, and their
enantiopure chains lie in the same crystallographic direction
([111], the overlay is shown in Figure S20). The chains
formed in the orcinol cocrystal (Figure 6a), on the other hand,
do not resemble those shown in Figure 5. While hydrogen
bonds are still formed to both of the carbonyl groups of PZQ
via its hydroxyl groups, a zigzag chain is visible (Figure 6b),
and chains with an equal chirality stack on top of each other.
For the cocrystals (and cocrystal solvate) with hydroquinone
(Figure 7a), 3,5-dihydroxybenzoic acid (Figure 7b) and 2,4-
dihydroxybenzoic acid (Figure 7c), hydrogen bonding patterns
induce the formation of chains containing both enantiomers of
PZQ (in a 1:1 molar ratio) and the coformer. Similar to the
above-mentioned enantiopure chains, both carbonyl groups of
the (alternating) PZQ enantiomers take part in hydrogen
bonding interactions with the coformer.
Contrary to the above-mentioned enantiopure and racemic
chains, a class of so-called racemic pair cocrystals was identified
where the (R)- and (S)-enantiomers of PZQ interact via
hydrogen bonding interactions similar to those found in the
racemic compound polymorph of pure PZQ with refcode
TELCEU0132 (Figure 8a). The formation of this pair was
observed for the cocrystals with vanillic acid (Figure 8c) and,
albeit shifted, 3,5-dinitrobenzoic acid (Figure 8d). For the
Figure 6. (a) Structure of the cocrystal containing (S)-PZQ and
orcinol (29). (b) Enantiopure zigzag chain of (S)-PZQ and orcinol
running along the [010] direction. Chains with an identical chirality
stack on top of each other. Only PZQ’s major conformation and the
hydrogen atoms relevant for hydrogen bonding and chirality are
shown (see the ESI for more details).
Figure 7. Cocrystals of PZQ connected by racemic chains. Only
hydrogen atoms involved in hydrogen bonding interactions and those
explanatory for the absolute configuration are displayed. For clarity,
only the major conformation is shown in case of disorder (ORTEP
plots with disorder and details are available in the ESI). (a) Cocrystal
with hydroquinone (15). (b) Cocrystal solvate with 3,5-dihydrox-
ybenzoic acid (24) and MeCN. (c) Cocrystal with 2,4-hydrox-
ybenzoic acid (28).
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cocrystal with salicylic acid, a hydrate is formed where the
enantiomers are bridged in a similar fashion as that for
TELCEU01. However, they are now bridged via two water
molecules (Figure 8b).
In contrast to the other coformers suggested by the network-
based link prediction, 1,4-diiodotetrafluorobenzene (6) is the
only molecule for which hydrogen bonding is precluded,
leaving halogen bonding and π−π interactions as plausible
alternatives for cocrystal formation. Unlike the apparent zero-
or one-dimensional nature of the interactions observed in the
former three classes, the structure of the cocrystal of 1,4-
diiodotetrafluorobenzene reveals a two-dimensional network
(Figure 9). Besides the alternation of PZQ enantiomers
halogen-bonded to the coformer via carbonyl-iodide inter-
actions on either side, the fluorine atoms of the coformer
interact with the hydrogens of the aromatic and cyclohexyl
rings of PZQ.
4. DISCUSSION
The availability of cocrystallization data facilitates the
application of the network-based link-prediction method.
Using eight known PZQ cocrystals as present in the CSD,
the method is able to propose a variety of chemically diverse
new coformers for PZQ. Sometimes related, yet in some cases
rather different (e.g., 1,4-diiodotetrafluorobenzene) coformers
are suggested. The algorithm performs a targeted search in the
cocrystal network for coformer candidates that exhibit a similar
tendency to form cocrystals as the coformers found in the list
of known cocrystals for PZQ and ranks them according to their
estimated scores or precision values. The latter can be
interpreted as the success rate of finding a new cocrystal
form. Given a sufficiently large test set, the expected number of
new cocrystals can be calculated by a weighted summation of
the precision values. The number of hits, i.e., the new
cocrystals for PZQ, agrees with this expected number of nine.
Eight new binary cocrystals and an additional four cocrystal
solvates were discovered, all of which were characterized by
SC-XRD. With this new extended information on cocrystals for
PZQ, the link-prediction method can be applied again, and an
updated and more precise list of coformer candidates can be
generated. To illustrate this concept, the coformer update was
performed once for PZQ, and the resulting top 50 predictions
are presented in Table S7. Alternatively, the obtained
information on both positive and negative indications for
cocrystal formation can be fed into a cocrystal prediction
framework based on artificial neural networks,50 further
guiding the search for adequate coformers. The latter classifies
coformers into plausible and unlikely candidates and finds its
primary use in the earliest stages of cocrystal screening when
no information about a molecule’s ability to form cocrystals is
known. Once experimental data become available, however, a
combined approach using the ranking and precisions obtained
from link prediction and the discrimination from neural
networks may be employed to guide the screening process.
In the set of 12 new cocrystal structures for Praziquantel,
four structural classes can be identified based on the packing of
PZQ molecules and the hydrogen bonding patterns present.
Similar to the PZQ cocrystals with adipic, glutaric, succinic,
oxalic, maleic, and fumaric acid reported by Espinosa-Lara et
al.29 (coformers b−d and f−h, respectively, in Figure 2),
coformers containing two hydrogen bond donors usually fulfill
Figure 8. Structures of a racemic compound polymorph of PZQ
(TELCEU01) and three cocrystals resembling its racemic pair
formation. (a) Racemic polymorph of Praziquantel (TELCEU01).32
(b) Cocrystal hydrate with salicylic acid (5). (c) Cocrystal with
vanillic acid (20). (d) Cocrystal with 3,5-dinitrobenzoic acid (13).
Only PZQ’s major conformation and the hydrogen atoms relevant for
hydrogen bonding and chirality are shown (detail in the ESI).
Figure 9. Racemic halogen-bonded network structure obtained for
the cocrystal of PZQ and 1,4-diiodotetrafluorobenzene (6). Only the
hydrogen atoms relevant for the determination of the absolute
configuration are shown. The cyclohexyl ring of PZQ is disordered,
and its major conformation is shown (details in the ESI).
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an effective bridging function as part of enantiopure chains of
PZQ molecules. Some of the coformers in these chains appear
to be interchangeable, leading to remarkable similarities in the
obtained unit cell parameters and intermolecular distances.
Apparently, this feature, which is not exclusive to cocrystal
forms of PZQ, is embedded in the coformer network and can
successfully be extracted via link prediction. Additionally, these
forms highlight a reliable pathway for the cocrystal formation
of PZQ with coformers characterized by a similar hydrogen
bond donor site separation and geometry. Differences in the
substitution pattern of hydroxybenzoic acid derivatives can,
however, result in a change in the structural class (e.g.,
containing racemic instead of enantiopure chains), demon-
strating the flexibility of PZQ to adopt various packings and
adapt to a specific coformer. Surprisingly, this adaptability of
PZQ for different types of coformers is also stored in the
network.
It can be envisaged that, besides solvate and hydrate
formation, cocrystal polymorphism is possible for PZQ given
the various structural classes observed. Whereas single-donor
molecules such as salicylic (5) and 3,5-dinitrobenzoic acid
(13) must rely on the aggregation of PZQ as in Figure 8a,
cocrystal formation with vanillic acid (20) can in principle lead
to different crystal packings. The different phases found for
vanillic acid during cocrystal screening are therefore probably
the result of cocrystal polymorphism. The same could be
assumed for 2,4-dihydroxybenzoic acid (28).
The structural exploration of the cocrystals of PZQ that
were predicted by link prediction revealed the dynamics and
flexibility of PZQ when it forms cocrystals. It also
demonstrates that information on cocrystal formation, such
as that present in the coformer network derived from the CSD,
can not always easily be replaced by chemical intuition. This
underlines the added value of our data-driven cocrystal
prediction method based on link prediction applied to CSD
data.
The cocrystal structures with achiral coformers studied here
are all centrosymmetric (containing both the (R)- and (S)-
enantiomer of PZQ). For the purpose of enantioseparation
using preferential crystallization or deracemization methods,
enantiomorphic structural classes different from those
discussed here should be discovered. Also, whereas not all of
the 30 considered coformers can be found on the so-called
GRAS listc, this study has unveiled several examples that
contain acceptable or drug-like molecules (e.g., salicylic acid, 4-
hydroxybenzoic acid, and 2,4- and 2,5-dihydroxybenzoic acid)
for which the pharmaceutical applicability may be further
investigated.
5. CONCLUSION
Using the information on eight known PZQ cocrystals present
in the CSD, network-based link prediction was successfully
used to propose several new coformers for PZQ. Seventeen
experimental indications for cocrystals were obtained, and
single crystals for 12 of the indications were resolved by SC-
XRD. Of these new cocrystalline materials, eight were found to
be two-component cocrystals, and four of them were found to
be cocrystal solvates, which is in line with the estimated nine
new combinations statistically expected from the predicted
precision values. A classification of the PZQ cocrystals was
performed based on the packing of the enantiomers and
intermolecular interactions between the coformers and PZQ,
demonstrating the concept of interchangeable, similar co-
formers.
This case study for PZQ showed how knowledge of a limited
set of known coformers for a target compound can be used to
generate meaningful network-based predictions for new
coformers given the cocrystal information in the CSD.
Experimental cocrystallization data gained from subsequent
cocrystal screening studies can easily be introduced to the
method as additional information, generating an even larger
and more precise list of predictions. We therefore envisage the
approach to be useful to researchers aiming to expand the
cocrystal landscape of target compounds on the basis of a
limited availability of in-house cocrystallization data.
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■ ADDITIONAL NOTES
aThe Biopharmaceutics Classification System classifies drugs
into four categories based on their solubility and permeability.
Class II corresponds to low solubility and high permeability.
bIn principle, nine PZQ cocrystals can be found in the CSD at
the time of writing this article, seven of which are with
dicarboxylic acids, one of which is with L-malic acid, and one of
which is with D-malic acid. However, the network approach
represents cocrystals with chiral molecules by using a single
enantiomer as one of its nodes (see ref 46), reducing the total
number to eight.
cGenerally recognized as safe. This is a list published by the
FDA specifying which substances are approved to be added to
drugs or food.
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